



KP TISSUE INC.

UNAUDITED CONDENSED FINANCIAL STATEMENTS

**FOR THE 3-MONTH PERIODS ENDED MARCH 31, 2026
AND MARCH 31, 2025**

KP Tissue Inc.

2 Prologis Blvd., Suite 500, Mississauga, Ontario L5W 0G8
www.kptissueinc.com

KP Tissue Inc.
Unaudited Condensed Statements of Financial Position

(tabular amounts are in thousands of Canadian dollars)

	Note	March 31, 2026 \$	December 31, 2025 \$
Assets			
Current assets			
Dividends receivable		1,804	1,803
		1,804	1,803
Non-current assets			
Investment in associate	5	71,080	69,799
Total assets		72,884	71,602
Liabilities			
Current liabilities			
Dividend payable	6	1,804	1,803
Total liabilities		1,804	1,803
Equity			
Common shares	6	23,073	23,001
Contributed surplus		144,819	144,819
Deficit		(114,193)	(114,985)
Accumulated other comprehensive income		17,381	16,964
Total equity		71,080	69,799
Total liabilities and equity		72,884	71,602

The accompanying notes are an integral part of these unaudited condensed financial statements.

KP Tissue Inc.

Unaudited Condensed Statements of Income and Comprehensive Income

For the 3-month periods ended March 31, 2026 and March 31, 2025

(tabular amounts are in thousands of Canadian dollars, except share and per share amounts)

	Note	3-month period ended March 31, 2026 \$	3-month period ended March 31, 2025 \$
Share of income		2,390	1,917
Depreciation of fair value increments		(270)	(284)
Equity income		2,120	1,633
Dilution gain		59	114
Net income		2,179	1,747
Other comprehensive income (loss) net of income tax expense (recovery)	6		
Items that will not be reclassified to net income:			
Remeasurements of pensions		331	(386)
Remeasurements of post-retirement benefits		87	(58)
Items that may be subsequently reclassified to net income:			
Cumulative translation adjustment		417	(123)
Other comprehensive income (loss)		835	(567)
Total comprehensive income		3,014	1,180
Basic and diluted earnings per share		0.22	0.17
Weighted average number of shares outstanding		10,021,253	9,993,168

The accompanying notes are an integral part of these unaudited condensed financial statements.

KP Tissue Inc.

Unaudited Condensed Statements of Changes in Equity

For the 3-month periods ended March 31, 2026 and March 31, 2025

(tabular amounts are in thousands of Canadian dollars, except share amounts)

	Note	Share capital #	Share capital \$	Contributed surplus \$	Deficit \$	Accumulated other comprehensive income \$	Total equity \$
As of January 1, 2026		10,015,366	23,001	144,819	(114,985)	16,964	69,799
Issuance of common shares	6	6,971	71	—	—	—	71
Dividends payable	6	—	—	—	(1,804)	—	(1,804)
Fair value adjustment		—	1	—	(1)	—	—
Remeasurement of pensions		—	—	—	331	—	331
Remeasurement of post-retirement benefits		—	—	—	87	—	87
Cumulative translation adjustment		—	—	—	—	417	417
Net income		—	—	—	2,179	—	2,179
As of March 31, 2026		10,022,337	23,073	144,819	(114,193)	17,381	71,080

	Note	Share capital #	Share capital \$	Contributed surplus \$	Deficit \$	Accumulated other comprehensive income \$	Total equity \$
As of January 1, 2025		9,987,547	22,762	144,819	(116,673)	18,609	69,517
Issuance of common shares	6	6,656	54	—	—	—	54
Dividends payable	6	—	—	—	(1,799)	—	(1,799)
Fair value adjustment		—	—	—	(386)	—	(386)
Remeasurement of post-retirement benefits		—	—	—	(58)	—	(58)
Cumulative translation adjustment		—	—	—	—	(123)	(123)
Net income		—	—	—	1,747	—	1,747
As of March 31, 2025		9,994,203	22,816	144,819	(117,169)	18,486	68,952

The accompanying notes are an integral part of these unaudited condensed financial statements.

KP Tissue Inc.

Unaudited Condensed Statements of Cash Flows

For the 3-month periods ended March 31, 2026 and March 31, 2025

(tabular amounts are in thousands of Canadian dollars)

	Note	3-month period ended March 31, 2026 \$	3-month period ended March 31, 2025 \$
Cash flows from (used in) operating activities			
Net income		2,179	1,747
Items not affecting cash			
Equity income		(2,120)	(1,633)
Dilution gain		(59)	(114)
Total items not affecting cash		(2,179)	(1,747)
Net cash from operating activities		—	—
Cash flows from (used in) investing activities			
Dividends received, net	6	1,732	1,744
Net cash from investing activities		1,732	1,744
Cash flows from (used in) financing activities			
Dividends paid, net	6	(1,732)	(1,744)
Net cash used in financing activities		(1,732)	(1,744)
Increase in cash and cash equivalents during the period		—	—
Cash and cash equivalents - Beginning of period		—	—
Cash and cash equivalents - End of period		—	—

The accompanying notes are an integral part of these unaudited condensed financial statements.

KP Tissue Inc.

Notes to Unaudited Condensed Financial Statements

For the 3-month periods ended March 31, 2026 and March 31, 2025

(tabular amounts are in thousands of Canadian dollars, except share and per share amounts)

1 GENERAL INFORMATION

KP Tissue Inc. (KPT or the Corporation) was incorporated by articles of incorporation under the Canadian Business Corporations Act on October 1, 2012. As of March 31, 2026, the Corporation held a 12.1% interest in Kruger Products Inc. (Kruger Products) (December 31, 2025 - 12.1%).

Kruger Products' principal business is to produce, distribute, market and sell a wide range of disposable tissue products, including bathroom tissue, facial tissue, paper towels and napkins for both the consumer and away-from-home markets in North America. The Corporation's headquarters are located in Mississauga, Ontario, Canada.

2 BASIS OF PRESENTATION

These unaudited condensed financial statements have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (IFRS Accounting Standards) applicable to the preparation of interim financial statements, including International Accounting Standards (IAS) 34 – Interim Financial Reporting as issued by the International Accounting Standards Board (IASB), and with interpretations of the International Financial Reporting Committee which the Canadian Accounting Standards Board has approved for incorporation into Part 1 of the CPA Canada Handbook - Accounting. These unaudited condensed financial statements should be read in conjunction with the annual audited financial statements of the Corporation for the year ended December 31, 2025.

These audited condensed financial statements were approved by the board of directors on May 13, 2026.

3 SUMMARY OF MATERIAL ACCOUNTING POLICIES

The material accounting policies used in the preparation of these unaudited condensed financial statements were disclosed in the annual audited financial statements of the Corporation for the year ended December 31, 2025 and have been applied to all periods presented.

(a) Accounting standard implemented effective January 1, 2026

Amendments to IFRS 9 and IFRS 7 - Amendments to the Classification and Measurement of Financial Instruments

On May 30, 2024, the IASB issued amendments to IFRS Accounting Standards 9 and IFRS Accounting Standards 7 aimed at improving the classification and measurement of financial instruments. The recent amendments simplify financial reporting by allowing earlier recognition of liabilities settled via electronic payments, clarifying the assessment of cash flows for basic lending arrangements, and refining definitions for non-recourse features and linked instruments. The amendments also introduce more detailed disclosure requirements for fair value changes in equity instruments and mandate reporting of terms that could affect cash flow timings or amounts. The amendments are effective for periods beginning on or after January 1, 2026 and adoption of these amendments did not have a material effect on the Company's condensed interim consolidated financial statements. For financial liabilities settled in cash using an electronic payment system, the election was applied to deem these financial liabilities to be discharged before the settlement date. The amendments have been applied retrospectively with no restatement of comparative information, in accordance with transition requirements on initial application of IFRS9.

KP Tissue Inc.

Notes to Unaudited Condensed Financial Statements

For the 3-month periods ended March 31, 2026 and March 31, 2025

(tabular amounts are in thousands of Canadian dollars, except share and per share amounts)

(b) Accounting standard issued but not yet implemented:

(i) IFRS 18, Presentation and Disclosure in Financial Statements

In April 2024, the IASB issued IFRS 18 to achieve comparability of the financial performance of similar entities. The standard, which replaces IAS 1, impacts the presentation of primary financial statements and notes, mainly the income statement where companies will be required to present separate categories of income and expense for operating, investing, and financing activities with prescribed subtotals for each new category. IFRS 18 will require management-defined performance measures to be explained and included in a separate note within the unaudited condensed financial statements. The mandatory effective date would be for annual reporting periods beginning on or after January 1, 2027, including interim financial statements, and requires retrospective application. The Corporation is currently assessing the impact of the new standard.

4 CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS

The preparation of these unaudited condensed financial statements in conformity with IFRS Accounting Standards requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities in the unaudited condensed financial statements and the disclosure of contingencies at the dates of the unaudited condensed statement of financial position, and the reported amounts of revenues and expenses during the reporting period. On a regular basis and with the information available, management reviews its estimates and judgments, including those related to fair value and the basis of accounting. Actual results could differ from those estimates. When adjustments become necessary, they are reported in earnings in the period in which they occur.

The estimates and judgement applied by management that most significantly affect the unaudited condensed financial statements are the same as the ones that applied to the annual audited financial statements for the year ended December 31, 2025.

5 INVESTMENT IN ASSOCIATE

Changes in the carrying amount of the investment were as follows:

	March 31, 2026	March 31, 2025
	\$	\$
Opening balance	69,799	69,517
Increase in investment	71	54
Share of income	2,390	1,917
Depreciation of fair value increments	(270)	(284)
Share of other comprehensive income (loss)	835	(567)
Dilution gain	59	114
Dividends	(1,804)	(1,799)
Closing balance	71,080	68,952

KP Tissue Inc.

Notes to Unaudited Condensed Financial Statements

For the 3-month periods ended March 31, 2026 and March 31, 2025

(tabular amounts are in thousands of Canadian dollars, except share and per share amounts)

The following summarizes financial information about the assets, liabilities, revenue and net income of Kruger Products, in which the Corporation holds a 12.1% interest as of March 31, 2026. The financial information was derived from the unaudited condensed financial statements of Kruger Products for the 3-month period ended March 31, 2026. The assets and liabilities disclosed include the fair value adjustments made to the carrying amount of the assets and liabilities of the associate on its acquisition.

	Kruger Products basis of accounting \$	Fair value increment \$	March 31, 2026 KPT basis of accounting \$
Current assets	690,670	—	690,670
Non-current assets	1,910,289	289,367	1,910,578
Liabilities	1,877,756	—	1,877,756
Net assets	723,203		

	3-month period ended March 31, 2026 \$
Revenue	544,646
Net income attributable to Kruger Products	19,772
Other comprehensive income	6,588
Total comprehensive income attributable to Kruger Products	26,360

	Kruger Products basis of accounting \$	Fair value increment \$	December 31, 2025 KPT basis of accounting \$
Current assets	678,083	—	678,083
Non-current assets	1,930,621	291,198	2,221,819
Liabilities	1,902,159	—	1,902,159
Net assets	706,545		

	3-month period ended March 31, 2025 \$
Revenue	546,110
Net income attributable to Kruger Products	15,395
Other comprehensive loss	(3,772)
Total comprehensive income attributable to Kruger Products	11,623

KP Tissue Inc.
Notes to Unaudited Condensed Financial Statements
For the 3-month periods ended March 31, 2026 and March 31, 2025

(tabular amounts are in thousands of Canadian dollars, except share and per share amounts)

The following shows the reconciliation of KPT's portion of Kruger Products equity to the investment recorded in KPT:

	March 31, 2026	December 31, 2025
	\$	\$
Kruger Products consolidated equity	723,203	706,545
Add back: Inception value of common shares	118,562	118,562
Less: Equity pertaining to Kruger Inc. and KPGP	(690,446)	(675,242)
Equity pertaining to KPT	151,319	149,865
Investment in associate recorded in KPT	71,080	69,799
Reconciling difference	80,239	80,066
Reconciling items since inception:		
Equity issuance costs	(11,110)	(11,110)
Depreciation of fair value increments	62,823	62,553
Currency translation adjustment in fair value increments	(2,867)	(2,829)
Tax Distribution	9,181	9,181
Gain on exercise of overallotment option	(375)	(375)
Dilution gain	(5,413)	(5,354)
Impairment in investment in associate	28,000	28,000
	—	—

With respect to KPT's investment in Kruger Products, the liability of KPT for the debts, liabilities and other obligations of Kruger Products is limited to KPT's capital contribution to Kruger Products.

6 DIVIDENDS

During the 3-month periods ended March 31, 2026 and March 31, 2025, the Corporation paid a quarterly dividend of \$0.18 per share to shareholders. Pursuant to the Corporation Dividend Reinvestment Plan (DRIP), a portion of the dividend was reinvested by the shareholders, resulting in the Corporation issuing common shares. The proceeds were used to acquire additional shares of Kruger Products. The dividends paid, the additional common shares issued at the share price, and the gross proceeds were as follows:

				2026
	Dividends paid	Share price	Issuance of Common Shares	Gross proceeds
Dividend Payment Date	\$	\$	#	\$
January 15, 2026	1,803	10.21	6,971	71

				2025
	Dividends paid	Share price	Issuance of Common Shares	Gross proceeds
Dividend Payment Date	\$	\$	#	\$
January 15, 2025	1,798	8.06	6,656	54

Subsequent to March 31, 2026, on April 15, 2026, the Corporation paid a dividend of \$1.8 million to shareholders at \$0.18 per common share. Pursuant to the Corporation DRIP, a portion of the dividend was reinvested by the shareholders, resulting in the Corporation issuing 5,375 common shares at a price of \$11.27.

Subsequent to March 31, 2026, the Corporation declared a dividend of \$2.1 million, payable on July 15, 2026.

KP Tissue Inc.

Notes to Unaudited Condensed Financial Statements

For the 3-month periods ended March 31, 2026 and March 31, 2025

(tabular amounts are in thousands of Canadian dollars, except share and per share amounts)

As a result of the DRIP and Kruger Inc.'s reinvestment of its dividends from Kruger Products in common shares of Kruger Products, a dilution gain of \$0.1 million was recorded during the 3-month period ended March 31, 2026 (3-month period ended March 31, 2025 - \$0.1 million).

7 ECONOMIC DEPENDENCE

The Corporation was created to acquire, and its business is limited to holding, a limited equity interest in Kruger Products, which is accounted for as an investment in an associate using the equity method of accounting. As such, the Corporation is economically dependent on Kruger Products and exposed to all the risks associated with the business of Kruger Products, including, but not limited to, liquidity risk.